Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3064571 | Journal of Neuroimmunology | 2011 | 8 Pages |
Abstract
A human recombinant T cell receptor ligand (RTL1000) consisting of DR2 α1 and β1 domains linked covalently to MOG-35-55 peptide can reverse clinical and histological signs of experimental autoimmune encephalomyelitis (EAE), and was evaluated for safety in a Phase 1 randomized, placebo-controlled, escalating dose study in 34 subjects with multiple sclerosis (MS). RTL1000 was safe and well tolerated at a dose of ≤ 60 mg that is well within the effective dose range for EAE and did not cause worsening of MS disease at doses ≤ 200 mg. RTL1000 represents a novel approach for the treatment of MS that promises potent immunoregulation and CNS repair without global immunosuppression.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Halina Offner, Sushmita Sinha, Gregory G. Burrows, Adolph J. Ferro, Arthur A. Vandenbark,